Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies

References

• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
• Pinard MA, Mahon B, McKenna R. Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors. Biomed Res Int 2015;2015:453543.
   PubMed Web of Science ®Google Scholar
• Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ. Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites. 2018;8:13.
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Uemura H, Hirao Y, Yoshida K, Saga S, Yoshikawa K. Radiation hybrid mapping of the human MN/CA9 locus to chromosome band 9p12-p13. Genomics. 1998;53:118–19.
   PubMed Web of Science ®Google Scholar
• Opavský R, Pastoreková S, Zelník V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996;33:480–87.
   PubMed Web of Science ®Google Scholar
• Waheed A, Sly WS, Doisy EA. Carbonic anhydrase XII functions in health and disease. Gene 2017;623:33–40.
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol. 2015;31:52–64.
   PubMed Web of Science ®Google Scholar
• Mboge MY, McKenna R, Frost SC. Advances in anti-cancer drug development targeting carbonic anhydrase IX and XII. Top Anticancer Res 2015;5:3–42
   PubMedGoogle Scholar
• Mahon BP, Pinard MA, McKenna R. Targeting carbonic anhydrase IX activity and expression. Molecules 2015;20:2323–48.
   PubMed Web of Science ®Google Scholar
• Singh S, Lomelino CL, Mboge MY, Frost SC, McKenna R. Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules 2018;23:1045.
   PubMed Web of Science ®Google Scholar
• Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F, Sly WS. Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem 2013;21:1570–82.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2010;1804:404–9.
   PubMed Web of Science ®Google Scholar
• Hulikova A, Zatovicova M, Svastova E, et al. Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett 2009;583:3563–8.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84–97.
   PubMed Web of Science ®Google Scholar
• Welch DR, Hurst DR. Defining the hallmarks of metastasis. Cancer Res 2019;79:3011–27.
   PubMed Web of Science ®Google Scholar
• Patel SA, Vanharanta S. Epigenetic determinants of metastasis. Mol Oncol 2017;11:79–96.
   PubMed Web of Science ®Google Scholar
• García SA, Weitz J, Schölch S. Circulating tumor cells. Methods Mol Biol 2018;1692:213–9.
   PubMedGoogle Scholar
• Balzer EM, Konstantopoulos K. Intercellular adhesion: mechanisms for growth and metastasis of epithelial cancers. Wiley Interdiscip Rev Syst Biol Med 2012;4:171–81.
   PubMed Web of Science ®Google Scholar
• Ratcliffe PJ. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol 2013;591:2027–42.
   PubMed Web of Science ®Google Scholar
• Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 2015;3:83–92.
   PubMed Web of Science ®Google Scholar
• Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett 2021;502:133–42.
   PubMed Web of Science ®Google Scholar
• Damaghi M, Wojtkowiak JW, Gillies RJ. pH sensing and regulation in cancer. Front Physiol 2013;4:370.
   PubMed Web of Science ®Google Scholar
• McIntyre A, Harris AL. The role of pH regulation in cancer progression. Recent Results Cancer Res 2016;207:93–134.
   PubMedGoogle Scholar
• Koltai T. Cancer: fundamentals behind pH targeting and the double-edged approach. Onco Targets Ther 2016;9:6343–60.
   PubMed Web of Science ®Google Scholar
• Parks SK, Pouysségur J. Targeting pH regulating proteins for cancer therapy-progress and limitations. Semin Cancer Biol 2017;43:66–73.
   PubMed Web of Science ®Google Scholar
• Asgharzadeh MR, Barar J, Pourseif MM, et al. Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. Bioimpacts 2017;7:115–33.
   PubMed Web of Science ®Google Scholar
• Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer 2017;3:169–80.
   PubMed Web of Science ®Google Scholar
• Li T, Le A. Glutamine metabolism in cancer. Adv Exp Med Biol 2018;1063:13–32.
   PubMed Web of Science ®Google Scholar
• Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020;5:28.
   PubMed Web of Science ®Google Scholar
• Miranda-Gonçalves V, Granja S, Martinho O, et al. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget 2016;7:46335–53.
   PubMedGoogle Scholar
• Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010;330:1340–4.
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341–52.
   PubMed Web of Science ®Google Scholar
• Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med 2008;359:2814–23.
   PubMed Web of Science ®Google Scholar
• Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393–402.
   PubMed Web of Science ®Google Scholar
• Lendahl U, Lee KL, Yang H, Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 2009;10:821–32.
   PubMed Web of Science ®Google Scholar
• Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006;281:25903–14.
   PubMed Web of Science ®Google Scholar
• Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL–/– renal cancer. Cancer Res 2005;65:5221–30.
   PubMed Web of Science ®Google Scholar
• Lee SH, Koo KH, Park JW, et al. HIF-1 is induced via EGFR activation and mediates resistance to anoikis-like cell death under lipid rafts/caveolae-disrupting stress. Carcinogenesis 2009;30:1997–2004.
   PubMed Web of Science ®Google Scholar
• El Guerrab A, Zegrour R, Nemlin CC, et al. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLOS One 2011;6:e25080.
   PubMed Web of Science ®Google Scholar
• Zhang Q li, Cui B ri, Li H yan, et al. MAPK and PI3K pathways regulate hypoxia-induced atrial natriuretic peptide secretion by controlling HIF-1 alpha expression in beating rabbit atria. Biochem Biophys Res Commun 2013;438:507–12.
   PubMed Web of Science ®Google Scholar
• Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013–9.
   PubMed Web of Science ®Google Scholar
• Khandrika L, Lieberman R, Koul S, et al. Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 2009;28:1248–60.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yao L, Yang J, Wang Z, Du G. PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia. Mol Med Rep 2018;18:3547–54.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:363–9.
   PubMedGoogle Scholar
• Ditte P, Dequiedt F, Svastova E, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res 2011;71:7558–67.
   PubMed Web of Science ®Google Scholar
• Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer 2017;17:577–93.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075–83.
   PubMed Web of Science ®Google Scholar
• Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19:3660–8.
   PubMed Web of Science ®Google Scholar
• Hynninen P, Vaskivuo L, Saarnio J, et al. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 2006;49:594–602.
   PubMed Web of Science ®Google Scholar
• Panisova E, Kery M, Sedlakova O, et al. Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget 2017;8:77819–35.
   PubMedGoogle Scholar
• Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013;12:1791–801.
   PubMed Web of Science ®Google Scholar
• Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009;1795:162–72.
   PubMed Web of Science ®Google Scholar
• Stillebroer AB, Mulders PFA, Boerman OC, Oyen WJG, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75–83.
   PubMed Web of Science ®Google Scholar
• Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99:424–31.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang L, Chew SH, Hirayama T, Sekido Y, Toyokuni S. Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia. Redox Biol 2019;26:101297.
   PubMed Web of Science ®Google Scholar
• Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011;11:671–7.
   PubMed Web of Science ®Google Scholar
• Persi E, Duran-Frigola M, Damaghi M, et al. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 2018;9:2997.
   PubMed Web of Science ®Google Scholar
• Sansone P, Piazzi G, Paterini P, et al. Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med 2009;13:3876–87.
   PubMed Web of Science ®Google Scholar
• Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64():6160–5.
   PubMed Web of Science ®Google Scholar
• Swayampakula M, McDonald PC, Vallejo M, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene 2017;36:6244–61.
   PubMed Web of Science ®Google Scholar
• Radvak P, Repic M, Svastova E, et al. Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncol Rep 2013;29:1147–53.
   PubMed Web of Science ®Google Scholar
• Fujiwara D, Kato K, Nohara S, Iwanuma Y, Kajiyama Y. The usefulness of three-dimensional cell culture in induction of cancer stem cells from esophageal squamous cell carcinoma cell lines. Biochem Biophys Res Commun 2013;434:773–8.
   PubMed Web of Science ®Google Scholar
• Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S. Hypoxia-induced dedifferentiation of tumor cells–a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16:554–63.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 2013;32:5210–9.
   PubMed Web of Science ®Google Scholar
• Currie MJ, Beardsley BE, Harris GC, et al. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol 2013;44:402–11.
   PubMed Web of Science ®Google Scholar
• Svastová E, Zilka N, Zat’ovicová M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003;290:332–45.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Rho SB, Jung DC, Han IO, Oh ES, Kim JY. Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci 2011;124:1077–87.
   PubMed Web of Science ®Google Scholar
• Bourguignon LYW, Singleton PA, Diedrich F, Stern R, Gilad E. CD44 interaction with Na+-H + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004;279:26991–7007.
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem 2001;276:7327–36.
   PubMed Web of Science ®Google Scholar
• Csaderova L, Debreova M, Radvak P, et al. The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Front Physiol 2013;4:271.
   PubMed Web of Science ®Google Scholar
• Riemann A, Rauschner M, Gießelmann M, Reime S, Haupt V, Thews O. Extracellular acidosis modulates the expression of epithelial-mesenchymal transition (EMT) markers and adhesion of epithelial and tumor cells. Neoplasia. 2019;21:450–8.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 2019;38:65–77.
   PubMed Web of Science ®Google Scholar
• Jamali S, Klier M, Ames S, et al. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci Rep 2015;5:13605.
   PubMed Web of Science ®Google Scholar
• Deitmer JW, Theparambil SM, Ruminot I, Becker HM. The role of membrane acid/base transporters and carbonic anhydrases for cellular pH and metabolic processes. Front Neurosci 2015;8:430.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites 2018;8:E20.
   PubMed Web of Science ®Google Scholar
• Pore N, Jalla S, Liu Z, et al. In vivo loss of function screening reveals carbonic anhydrase IX as a key modulator of tumor initiating potential in primary pancreatic tumors. Neoplasia 2015;17:473–80.
   PubMed Web of Science ®Google Scholar
• Zandberga E, Zayakin P, Ābols A, Pūpola D, Trapencieris P, Linē A. Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells. Cancer Biol Ther 2017;18:596–605.
   PubMed Web of Science ®Google Scholar
• Doyen J, Parks SK, Marcié S, Pouysségur J, Chiche J. Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Front Oncol 2013;2:199.
   PubMedGoogle Scholar
• Jiang L, Xu G, Li Z, et al. RNAi-mediated knockdown of CAIX enhances the radiosensitivity of nasopharyngeal carcinoma cell line, CNE-2. Onco Targets Ther 2017;10:4701–09.
   PubMed Web of Science ®Google Scholar
• Gut MO, Parkkila S, Vernerová Z, et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002;123:1889–1903.
   PubMed Web of Science ®Google Scholar
• Pan P wen, Parkkila AK, Autio S, et al. Brain phenotype of carbonic anhydrase IX-deficient mice. Transgenic Res 2012;21:163–76.
   PubMed Web of Science ®Google Scholar
• Li T, Liu X, Riederer B, et al. Genetic ablation of carbonic anhydrase IX disrupts gastric barrier function via claudin-18 downregulation and acid backflux. Acta Physiol 2018;222:e12923.
   PubMed Web of Science ®Google Scholar
• Pastoreková S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398–408.
   PubMed Web of Science ®Google Scholar
• Nordfors K, Haapasalo J, Korja M, et al. The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer 2010;10:148.
   PubMed Web of Science ®Google Scholar
• Ilie MI, Hofman V, Ortholan C, et al. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer 2011;128:1614–23.
   PubMed Web of Science ®Google Scholar
• Tafreshi NK, Lloyd MC, Proemsey JB, et al. Evaluation of CAIX and CAXII expression in breast cancer at varied O2 levels: CAIX is the superior surrogate imaging biomarker of tumor hypoxia. Mol Imaging Biol 2016;18:219–31.
   PubMed Web of Science ®Google Scholar
• Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Pohl F, Brawanski A. Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol 2012;14:1357–66.
   PubMed Web of Science ®Google Scholar
• Cetin B, Gonul II, Gumusay O, et al. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. Neuropathology 2018;38:457–62.
   PubMed Web of Science ®Google Scholar
• McIntyre A, Patiar S, Wigfield S, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 2012;18:3100–11.
   PubMed Web of Science ®Google Scholar
• Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011;8:2032–8.
   PubMed Web of Science ®Google Scholar
• Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003;13:1005–9.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
   PubMed Web of Science ®Google Scholar
• McKenna R, Supuran CT. Carbonic anhydrase inhibitors drug design. Subcell Biochem 2014;75:291–323.
   PubMedGoogle Scholar
• Anduran E, Aspatwar A, Parvathaneni NK, et al. Hypoxia-activated prodrug derivatives of carbonic anhydrase inhibitors in benzenesulfonamide series: synthesis and biological evaluation. Molecules 2020;25:E2347.
   PubMed Web of Science ®Google Scholar
• Wong BCK, Zhang H, Qin L, et al. Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Drug Des Devel Ther 2014;8:993–1001.
   PubMed Web of Science ®Google Scholar
• Ng HLH, Lu A, Lin G, Qin L, Yang Z. The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo. Int J Mol Sci 2014;16:230–55.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 2012;55:5591–600.
   PubMed Web of Science ®Google Scholar
• Ahlskog JKJ, Dumelin CE, Trüssel S, Mårlind J, Neri D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett. 2009;19:4851–56.
   PubMed Web of Science ®Google Scholar
• Cianchi F, Vinci MC, Supuran CT, et al. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 2010;334:710–9.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902.
   PubMed Web of Science ®Google Scholar
• Vannozzi G, Vullo D, Angeli A, et al. One-pot procedure for the synthesis of asymmetric substituted ureido benzene sulfonamides as effective inhibitors of carbonic anhydrase enzymes. J Med Chem. 2022;65:824–37.
   PubMedGoogle Scholar
• Koyuncu I, Tülüce Y, Slahaddin Qadir H, Durgun M, Supuran CT. Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells. J Enzyme Inhib Med Chem 2019;34:703–11.
   PubMed Web of Science ®Google Scholar
• Tülüce Y, Ahmed BA, Koyuncu İ, Durgun M. The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells. J Bioenerg Biomembr 2018;50:107–16.
   PubMed Web of Science ®Google Scholar
• Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;46:2197–204.
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem 2015;30:689–721.
   PubMed Web of Science ®Google Scholar
• Hektoen HH, Ree AH, Redalen KR, Flatmark K. Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells. J Enzyme Inhib Med Chem 2016;31:779–86.
   PubMed Web of Science ®Google Scholar
• Ward C, Meehan J, Mullen P, et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget 2015;6:24856–70.
   PubMed Web of Science ®Google Scholar
• Raez L, Samuels M, Lilenbaum R. Combined modality therapy for limited-disease small cell lung cancer. Curr Treat Options Oncol 2005;6:69–74.
   PubMedGoogle Scholar
• Bryant JL, Gieling RG, Meredith SL, et al. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer 2018;142:191–201.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Parker CA, De Costa LA, et al. Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. J Enzyme Inhib Med Chem 2013;28:360–369.
   PubMed Web of Science ®Google Scholar
• Buller F, Steiner M, Frey K, et al. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem Biol. 2011;6:336–44.
   PubMed Web of Science ®Google Scholar
• Tykvart J, Navrátil V, Kugler M, et al. Identification of novel carbonic anhydrase IX inhibitors using high-throughput screening of pooled compound libraries by DNA-linked inhibitor antibody assay (DIANA). SLAS Discov 2020;25:1026–37.
   PubMed Web of Science ®Google Scholar
• Chahal V, Nirwan S, Pathak M, Kakkar R. Identification of potent human carbonic anhydrase IX inhibitors: a combination of pharmacophore modeling, 3D-QSAR, virtual screening and molecular dynamics simulations. J Biomol Struct Dyn 2020;15:1–16.
   Google Scholar
• Lomelino CL, Murray AB, Supuran CT, McKenna R. Sweet binders: carbonic anhydrase IX in complex with sucralose. ACS Med Chem Lett 2018;9:657–61.
   PubMed Web of Science ®Google Scholar
• Cuffaro D, Nuti E, Rossello A. An overview of carbohydrate-based carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020;35:1906–22.
   PubMed Web of Science ®Google Scholar
• Winum JY, Colinas PA, Supuran CT. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. Bioorg Med Chem 2013;21:1419–26.
   PubMed Web of Science ®Google Scholar
• Andreucci E, Ruzzolini J, Peppicelli S, et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019;34:117–23.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Andreucci E, Ruzzolini J, et al. The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells. J Enzyme Inhib Med Chem 2020;35:1185–93.
   PubMed Web of Science ®Google Scholar
• Riemann A, Güttler A, Haupt V, et al. Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity. Oncol Res 2018;26:191–200.
   PubMed Web of Science ®Google Scholar
• Mussi S, Rezzola S, Chiodelli P, Nocentini A, Supuran CT, Ronca R. Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines. J Enzyme Inhib Med Chem 2022;37:280–286.
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10:412.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27:963–70.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 2020;43:484–90.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2021;30:1197–208.
   PubMed Web of Science ®Google Scholar
• Elimam DM, Eldehna WM, Salem R, et al. Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors. Eur J Med Chem 2022;228:114008.
   PubMed Web of Science ®Google Scholar
• Elbadawi MM, Eldehna WM, Nocentini A, et al. Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: synthesis and evaluation of the carbonic anhydrase inhibitory activities. Eur J Med Chem 2021;218:113360.
   PubMed Web of Science ®Google Scholar
• Shaldam M, Eldehna WM, Nocentini A, et al. Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors. Eur J Med Chem 2021;216:113283.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Gieling RG. Preclinical evaluation of ureidosulfamate carbonic anhydrase IX/XII inhibitors in the treatment of cancers. Int J Mol Sci 2019;20:E6080.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Combs J, Singh S, et al. Inhibition of carbonic anhydrase using SLC-149: support for a noncatalytic function of CAIX in breast cancer. J Med Chem 2021;64:1713–24.
   PubMed Web of Science ®Google Scholar
• Sarnella A, D’Avino G, Hill BS, et al. A novel inhibitor of carbonic anhydrases prevents hypoxia-induced TNBC cell plasticity. Int J Mol Sci 2020;21:8405.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Kalinin S, Sharonova T, Supuran CT. Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents. J Enzyme Inhib Med Chem 2020;35:1555–61.
   PubMed Web of Science ®Google Scholar
• Dvořanová J, Kugler M, Holub J, et al. Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX. Eur J Med Chem 2020;200:112460.
   PubMed Web of Science ®Google Scholar
• Kugler M, Holub J, Brynda J, et al. The structural basis for the selectivity of sulfonamido dicarbaboranes toward cancer-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem 2020;35:1800–10.
   PubMed Web of Science ®Google Scholar
• Sharma V, Kumar R, Angeli A, Supuran CT, Sharma PK. Tail approach synthesis of novel benzenesulfonamides incorporating 1,3,4-oxadiazole hybrids as potent inhibitor of carbonic anhydrase I, II, IX, and XII isoenzymes. Eur J Med Chem 2020;193:112219.
   PubMed Web of Science ®Google Scholar
• Uslu AG, Gür Maz T, Nocentini A, Banoglu E, Supuran CT, Çalışkan B. Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors. Bioorg Chem 2020;95:103544.
   PubMed Web of Science ®Google Scholar
• Pustenko A, Nocentini A, Balašova A, Krasavin M, Žalubovskis R, Supuran CT. 7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem 2020;35:650–6.
   PubMed Web of Science ®Google Scholar
• Pustenko A, Nocentini A, Balašova A, et al. Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020;35:245–54.
   PubMed Web of Science ®Google Scholar
• El-Azab AS, Abdel-Aziz AAM, Bua S, et al. S-substituted 2-mercaptoquinazolin-4(3H)-one and 4-ethylbenzensulfonamides act as potent and selective human carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem 2020;35:733–43.
   PubMed Web of Science ®Google Scholar
• Angeli A, Tanini D, Nocentini A, et al. Selenols: a new class of carbonic anhydrase inhibitors. Chem Commun. 2019;55:648–51.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Žalubovskis R, Grandāne A, Domračeva I, Zhmurov P, Supuran CT. Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Enzyme Inhib Med Chem 2020;35:506–10.
   PubMed Web of Science ®Google Scholar
• Buran K, Bua S, Poli G, Önen Bayram FE, Tuccinardi T, Supuran CT. Novel 8-substituted coumarins that selectively inhibit human carbonic anhydrase IX and XII. Int J Mol Sci 2019;20:E1208.
   PubMed Web of Science ®Google Scholar
• Chandra KM, Goud NS, Arifuddin M, et al. Synthesis and biological evaluation of novel 4,7-disubstituted coumarins as selective tumor-associated carbonic anhydrase IX and XII inhibitors. Bioorg Med Chem Lett 2021;39:127877.
   PubMed Web of Science ®Google Scholar
• Meleddu R, Deplano S, Maccioni E, et al. Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives. J Enzyme Inhib Med Chem 2021;36:685–92.
   PubMed Web of Science ®Google Scholar
• Thacker PS, Srikanth D, Angeli A, et al. Coumarin-thiourea hybrids show potent carbonic anhydrase IX and XIII inhibitory action. ChemMedChem 2021;16:1252–6.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev 2018;38:1799–836.
   PubMed Web of Science ®Google Scholar
• Angeli A, Peat TS, Selleri S, Saleh Alfawaz Altamimi A, Supuran CT, Carta F. X-ray crystallography of epacadostat in adduct with carbonic anhydrase IX. Bioorg Chem 2020;97:103669.
   PubMed Web of Science ®Google Scholar
• Akocak S, Güzel-Akdemir Ö, Kishore Kumar Sanku R, et al. Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII. Bioorg Chem 2020;103:104204.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Bua S, Lomelino CL, et al. Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous bases. ACS Med Chem Lett 2017;8:1314–9.
   PubMed Web of Science ®Google Scholar
• Li J, Shi K, Sabet ZF, et al. New power of self-assembling carbonic anhydrase inhibitor: short peptide-constructed nanofibers inspire hypoxic cancer therapy. Sci Adv 2019;5:eaax0937.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–580.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
• Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg Med Chem Lett 2009;19:4102–6.
   PubMed Web of Science ®Google Scholar
• Temperini C, Innocenti A, Mastrolorenzo A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett 2007;17:4866–72.
   PubMed Web of Science ®Google Scholar
• Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004;47:550–7.
   PubMed Web of Science ®Google Scholar
• Mahboubi-Rabbani M, Zarghi A. Dual human carbonic anhydrase/cyclooxygenase-2 inhibitors: a promising approach for cancer treatment. Anticancer Agents Med Chem 2021.
   PubMed Web of Science ®Google Scholar
• Cho EJ, Yu SJ, Kim K, et al. Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. J Bioenerg Biomembr 2019;51:121–9.
   PubMed Web of Science ®Google Scholar
• Shabana AM, Mondal UK, Alam MR, et al. pH-sensitive multiligand gold nanoplatform targeting carbonic anhydrase IX enhances the delivery of doxorubicin to Hypoxic tumor spheroids and overcomes the hypoxia-induced chemoresistance. ACS Appl Mater Interfaces 2018;10:17792–808.
   PubMed Web of Science ®Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight 2017;2:92928.
   PubMed Web of Science ®Google Scholar
• Logsdon DP, Grimard M, Luo M, et al. Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models. Mol Cancer Ther 2016;15:2722–32.
   PubMed Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Saberi S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res 2019;7:1064–78.
   PubMed Web of Science ®Google Scholar
• Ruzzolini J, Laurenzana A, Andreucci E, et al. A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. J Enzyme Inhib Med Chem 2020;35:391–7
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Monoclonal antibody G250 targeting CA IX: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol 2014;45:2455–67.
   PubMed Web of Science ®Google Scholar
• Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29:121–6.
   PubMed Web of Science ®Google Scholar
• Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90:985–90.
   PubMed Web of Science ®Google Scholar
• Testa C, Papini AM, Zeidler R, et al. First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. J Enzyme Inhib Med Chem 2022;37:592–6.
   PubMed Web of Science ®Google Scholar
• Antal I, Koneracka M, Kubovcikova M, et al. Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles. Colloids Surf B Biointerfaces 2021;205:111893.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Dal Corso A, Widmayer F, Neri D. Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J Am Chem Soc. 2018;140:1617–21.
   PubMed Web of Science ®Google Scholar
• Tatiparti K, Rauf MA, Sau S, Iyer AK. Carbonic anhydrase-IX guided albumin nanoparticles for hypoxia-mediated triple-negative breast cancer cell killing and imaging of patient-derived tumor. Molecules 2020;25:2362.
   PubMed Web of Science ®Google Scholar
• Santos E da S, Nogueira KAB, Fernandes LCC, et al. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm 2021;592:120082.
   PubMedGoogle Scholar
• Krall N, Pretto F, Decurtins W, Bernardes GJL, Supuran CT, Neri D. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–5.
   PubMed Web of Science ®Google Scholar
• Petrul HM, Schatz CA, Kopitz CC, et al. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther 2012;11:340–9.
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des 2010;16:3255–63.
   PubMed Web of Science ®Google Scholar
• Thacker PS, Alvala M, Arifuddin M, Angeli A, Supuran CT. Design, synthesis and biological evaluation of coumarin-3-carboxamides as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem 2019;86:386–92.
   PubMed Web of Science ®Google Scholar
• Thacker PS, Angeli A, Argulwar OS, Tiwari PL, Arifuddin M, Supuran CT. Design, synthesis and biological evaluation of coumarin linked 1,2,4-oxadiazoles as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem 2020;98:103739.
   PubMed Web of Science ®Google Scholar
• Thacker PS, Sridhar Goud N, Argulwar OS, et al. Synthesis and biological evaluation of some coumarin hybrids as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem 2020;104:104272.
   PubMed Web of Science ®Google Scholar
• Abdelrahman MA, Eldehna WM, Nocentini A, et al. Novel benzofuran-based sulphonamides as selective carbonic anhydrases IX and XII inhibitors: synthesis and in vitro biological evaluation. J Enzyme Inhib Med Chem 2020;35:298–305.
   PubMed Web of Science ®Google Scholar
• Abdelrahman MA, Ibrahim HS, Nocentini A, et al. Novel 3-substituted coumarins as selective human carbonic anhydrase IX and XII inhibitors: synthesis, biological and molecular dynamics analysis. Eur J Med Chem 2021;209:112897.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Chen Z, Wolff A, et al. Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: disconnect between activity and growth inhibition. PLOS One 2018;13:e0207417.
   PubMed Web of Science ®Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother 2011;60:649–58.
   PubMed Web of Science ®Google Scholar
• Gondi G, Mysliwietz J, Hulikova A, et al. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res 2013;73:6494–503.
   PubMed Web of Science ®Google Scholar
• von Neubeck B, Gondi G, Riganti C, et al. An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo. Int J Cancer 2018;143:2065–75.
   PubMed Web of Science ®Google Scholar
• Uda NR, Stenner F, Seibert V, et al. Humanized monoclonal antibody blocking carbonic anhydrase 12 enzymatic activity leads to reduced tumor growth in vitro. Anticancer Res 2019;39:4117–28.
   PubMed Web of Science ®Google Scholar
• Dekaminaviciute D, Kairys V, Zilnyte M, et al. Monoclonal antibodies raised against 167-180 aa sequence of human carbonic anhydrase XII inhibit its enzymatic activity. J Enzyme Inhib Med Chem 2014;29:804–10.
   PubMed Web of Science ®Google Scholar
• Moeker J, Peat TS, Bornaghi LF, Vullo D, Supuran CT, Poulsen SA. Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes. J Med Chem 2014;57:3522–31.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Taghour MS, Al-Warhi T, et al. Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem 2022;37:531–41.
   PubMed Web of Science ®Google Scholar
• Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget 2017;8:38022–43.
   PubMedGoogle Scholar
• Havránková E, Garaj V, Mascaretti Š, et al. Novel 1,3,5-triazinyl aminobenzenesulfonamides incorporating aminoalcohol, aminochalcone and aminostilbene structural motifs as potent anti-VRE agents, and carbonic anhydrases I, II, VII, IX, and XII inhibitors. Int J Mol Sci 2021;23:231.
   PubMed Web of Science ®Google Scholar
• Giovannuzzi S, D’Ambrosio M, Luceri C, et al. Aromatic sulfonamides including a sulfonic acid tail: new membrane impermeant carbonic anhydrase inhibitors for targeting selectively the cancer-associated isoforms. Int J Mol Sci 2021;23:461.
   PubMed Web of Science ®Google Scholar
• Abdel-Mohsen HT, El Kerdawy AM, Omar MA, et al. Application of the dual-tail approach for the design and synthesis of novel thiopyrimidine-benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors. Eur J Med Chem 2022;228:114004.
   PubMed Web of Science ®Google Scholar
• Eldeeb AH, Abo-Ashour MF, Angeli A, et al. Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail/dual tail approaches: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies. Eur J Med Chem 2021;221:113486.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang G, Wang X, Li XF. Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia? Future Oncol 2015;11:1531–41.
   PubMed Web of Science ®Google Scholar
• Adams A, van Brussel ASA, Vermeulen JF, et al. The potential of hypoxia markers as target for breast molecular imaging–a systematic review and meta-analysis of human marker expression. BMC Cancer 2013;13:538.
   PubMed Web of Science ®Google Scholar
• Mayer A, Höckel M, Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res 2005;11:7220–5.
   PubMed Web of Science ®Google Scholar
• Said HM, Supuran CT, Hageman C, et al. Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr Pharm Des 2010;16:3288–99.
   PubMed Web of Science ®Google Scholar
• Chamie K, Donin NM, Klöpfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 2017;3:913–20.
   PubMed Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem 2016;31:119–125.
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358–68.
   PubMed Web of Science ®Google Scholar
• Meijer TWH, Bussink J, Zatovicova M, et al. Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model. PLOS One. 2014;9:e108068.
   PubMed Web of Science ®Google Scholar
• Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 2017;171:1678–1691.e13.
   PubMed Web of Science ®Google Scholar
• Kalinin S, Malkova A, Sharonova T, et al. Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors. Int J Mol Sci 2021;22:13405.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1–11.
   PubMed Web of Science ®Google Scholar
• Topatana W, Juengpanich S, Li S, et al. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol 2020;13:118.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chafe SC, Brown WS, et al. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology 2019;157:823–37.
   PubMed Web of Science ®Google Scholar
• Song X, Zhu S, Xie Y, et al. JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice. Gastroenterology 2018;154:1480–93.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Verbiest T, Devery AM, et al. Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality. Int J Radiat Oncol Biol Phys 2016;95:772–81.
   PubMed Web of Science ®Google Scholar
• Teixeira SA, Viapiano MS, Andrade AF, et al. The carbonic anhydrase inhibitor E7070 sensitizes glioblastoma cells to radio- and chemotherapy and reduces tumor growth. Mol Neurobiol 2021;58:4520–34.
   PubMedGoogle Scholar
• Chafe SC, Vizeacoumar FS, Venkateswaran G, et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv 2021;7:eabj0364.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem. 2021;36:1702–14.
   PubMed Web of Science ®Google Scholar